SEC Form 424B5 filed by Entrada Therapeutics Inc.
(To prospectus dated November 7, 2022)
Pre-funded Warrants to Purchase 3,367,003 Shares of Common Stock
| | |
Per Share
|
| |
Per Pre-funded Warrant
|
| |
Total
|
| |||||||||
Offering price
|
| | | $ | 14.85 | | | | | $ | 14.8499 | | | | | $ | 99,999,652.40 | | |
PROSPECTUS SUPPLEMENT
|
| |
PAGE
|
| |||
| | | | S-i | | | |
| | | | S-1 | | | |
| | | | S-5 | | | |
| | | | S-7 | | | |
| | | | S-9 | | | |
| | | | S-12 | | | |
| | | | S-13 | | | |
| | | | S-15 | | | |
| | | | S-17 | | | |
| | | | S-21 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-22 | | | |
| | | | S-23 | | |
PROSPECTUS
|
| |
PAGE
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 6 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 15 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 26 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 30 | | |
Symbol
|
Purchase price per share
|
| | | | | | | | | $ | 14.85 | | |
|
Historical net tangible book value per share as of March 31, 2024
|
| | | $ | 8.02 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | | 1.96 | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | | 9.98 | | |
|
Dilution in net tangible book value per share to investors participating in this offering
|
| | | | | | | | | $ | 4.87 | | |
One Design Center Place, Suite 17-500
Boston, MA 02210
Attn: Investor Relations
(857) 520-9158
Preferred Stock
Debt Securities
Warrants
Units
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 6 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 15 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 26 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | |
6 Tide Steet
Boston, MA 02210
Attn: Investor Relations
(857) 520-9158
Pre-funded Warrants to Purchase 3,367,003 Shares of Common Stock